Filing Flows › Fate Therapeutics (FATE) › Q1 2026 › vs Q1 2025
Fate Therapeutics (FATE) Q1 2026 vs Q1 2025 (year over year)
Fate Therapeutics's revenue fell $330K (-20%) from $1.6M in Q1 2025 to $1.3M in Q1 2026.
Fate Therapeutics, Q1 2026: revenue $1.3M (-20% year over year), net loss $31.2M, operating cash flow −$30.8M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3M | $1.6M | −$330K | -20% |
| Other income, net | $1.8M | $3.7M | −$1.9M | -51% |
| Net loss | $31.2M | $37.6M | −$6.4M | -17% |
| Costs & expenses | $34.3M | $42.9M | −$8.6M | -20% |
| Operating costs | $34.3M | $42.9M | −$8.6M | -20% |
| Research & development | $24.7M | $29.1M | −$4.4M | -15% |
| General & admin | $9.6M | $13.8M | −$4.2M | -30% |
| Operating cash sources | $37.7M | $44.5M | −$6.9M | -15% |
| Depreciation & amortization | $2.9M | $3.3M | −$415K | -12% |
| Share-based compensation | $3.9M | $7.4M | −$3.5M | -47% |
| Cash used in operations | $30.8M | $33.8M | −$3.0M | -9% |
| Net loss absorbed | $31.2M | $37.6M | −$6.4M | -17% |
| Working capital & other | $6.5M | $6.9M | −$446K | -6% |
Questions
How much did Fate Therapeutics's revenue grow year over year in Q1 2026?
Fate Therapeutics's revenue fell $330K (-20%) from $1.6M in Q1 2025 to $1.3M in Q1 2026.